



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

A61N

A2

(11) International Publication Number:

WO 99/39765

(43) International Publication Date:

12 August 1999 (12.08.99)

(21) International Application Number: PCT/US99/02788

(22) International Filing Date: 9 February 1999 (09.02.99)

(30) Priority Data:

60/074,181

10 February 1998 (10.02.98)

US

(71) Applicant: IMPLANT SCIENCES CORPORATION [US/US];
107 Audubon Road #5, Wakefield, MA 01880-1246 (US).(72) Inventor: ARMINI, Anthony, J.; 5 Skytop Drive, Manches-
ter-by-the-Sea, MA 01944 (US).(74) Agent: CAMPBELL, Paula, A.; Foley, Hoag & Eliot, LLP,
One Post Office Square, Boston, MA 02109 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

Without international search report and to be republished upon receipt of that report.

(54) Title: SOFT X-RAY EMITTING MEDICAL DEVICES

(57) Abstract

An implantable medical device according to the present invention comprises a body, such as a stent or a wire, and an isotope having a high neutron activation cross section, such as ¹⁶⁸Yb or ¹²⁴Xe, ion-implanted onto the surface of the body. The use of isotopes having high neutron activation cross sections allows a wider choice of substrates to be employed, including stainless steel, nickel, titanium, and alloys including these metals, because the time required for neutron activation of the device is reduced. A coating of high-density material may be incorporated to serve several useful purposes; including containment of undesirable beta particles from long-lived radioactive species, creation of a biologically inert surface, and enhancement of x-ray radiopacity to improve the visibility of an implanted medical device. The implantable medical devices of the present invention also comprise radioactive medical devices which include radioisotopes such as ¹⁶⁹Yb and ¹²⁵I.



SOFT X-RAY EMITTING MEDICAL DEVICES

Related Applications

This application is based on and claims priority to provisional application No. 60/074,181 filed February 10, 1998, the entire disclosure of which is hereby
5 incorporated herein by reference.

Background

After balloon angioplasty, a metal tubular scaffold structure called a stent may be permanently implanted to physically hold open the repaired coronary artery. Unfortunately, up to 30% of such procedures result in narrowing or reclosure
10 (restenosis) of the artery within six months to one year. One solution to the problem is to provide acute local, postoperative radiation treatment of the site using a catheter tipped with iridium-192 radioisotope. In this method, called intra-vascular brachytherapy, the iridium-192-tipped catheter is placed at the arterial site for thirty to forty minutes after stent deployment and then retracted. This type of acute high dose
15 treatment using gamma radiation has been found to substantially reduce the rate of subsequent restenosis, as noted in Wiedermann, J.G. et al., "Intracoronary Irradiation Markedly Reduces Restenosis After Balloon Angioplasty in a Porcine Model," 23 J. Am. Coll. Cardiol., 1491-1498 (May 1994) and Teirstein, P.S. et al., "Catheter-Based Radiotherapy to Inhibit Restenosis After Coronary Stenting," 336 New England
20 Journal of Medicine, 1697-1703 (June 12, 1997).

This method of irradiating the patient suffers from the hazards associated with the required high radiation intensity. In addition to the surgeon, an oncologist and a radiation physicist are typically required for the procedure. A heavily shielded lead vault is needed to separate the patient from the operating room personnel, and the task of safely inserting the catheter containing the intense source, which is on the order of about 0.2 Curies, is particularly difficult. If irregularities occur in the procedure, the surgeon has relatively little time to respond, and therefore emergency procedures must be well-rehearsed. It is felt that this method, while possible in a research environment, may not be practical for normal usage.

An alternate method of addressing the restenosis problem is to use a permanently implanted radioactive stent, the method preferred by most physicians for its greater safety. Sources of radiation which are either pure beta particle or x-ray emitters are preferred because of the short range of the radiation, thus automatically protecting both the patient and the operating room personnel, particularly after the arterial insertion of the stent on the catheter.

As a result of studies in rabbits and swine, it is believed that a total dose of between 15 and 25 Grays is required to successfully inhibit restenosis in coronary arteries. Existing radioactive stent designs utilizing ion implantation of radioisotopes such as ^{32}P , ^{186}Re , ^{90}Y or ^{103}Pd require a highly specialized facility to perform the activations at considerable cost. U.S. Patents 5,050,166 and 5,376,617 to Fischell et al. describe radioactive stents wherein radioactive material is either placed within the stent body or is electroplated onto the surface. Other methods involving cyclotron

irradiation or coatings with radioactive liquids have contamination and safety problems respectively. Handling radioactive materials in these methods is difficult, expensive, and risky.

To avoid such difficult procedures, it is possible to ion-implant or coat a stent with a stable isotope, such as ^{31}P , ^{185}Re , ^{89}Y , or ^{102}Pd , which can be activated by neutron bombardment in order to generate a radioisotope, such as ^{32}P , ^{186}Re , ^{90}Y , or ^{103}Pd , respectively. In this manner, the stent would be fabricated in the absence of any radioactive species and then activated prior to implantation into the patient. The material used for the body of the stent to be activated must be carefully selected not to include elements that are easily activated by neutron bombardment to produce isotopes that give off undesirable radiation. For example, stainless steel, an otherwise ideal material, cannot be used in the above method because the neutron bombardment will activate the stent body to produce long-lived, high-energy gamma ray-emitting isotopes such as ^{51}Cr and ^{59}Fe , which are unacceptable in a permanently implanted stent.

Even small impurities in otherwise acceptable metals may give rise to harmful radiation. For example, Laird ("Inhibition of Neointimal Proliferation with Low-Dose Irradiation from a β -Particle-Emitting Stent", Laird J. R. et al., Circulation, 93, No. 3, Feb. 1996) ion-implanted a titanium stent with stable ^{31}P and generated the radioisotope ^{32}P by inserting the ion-implanted stent in a nuclear reactor. This technique produced only a very small amount of ^{32}P , and the trace impurities in the titanium body produced high energy gamma rays which were comparable in strength to

the desired ^{32}P radiation. This technique suffered from the fact that ^{31}P has a very small neutron activation cross-section (0.18 barns), and thereby requires a long activation time. Even though titanium itself does not activate with thermal neutrons to form long-lived radioisotopes, titanium does activate with fast neutrons to ^{46}Ti , having a long half-life of 83 days, and the high cross-section impurities in the titanium body produced too much harmful contaminating gamma radiation. These experiments on titanium stents suggest that ion implantation of stable isotopes into stainless steel stents would present even greater obstacles.

Summary of the Invention

The present invention comprises radioactive, x-ray-emitting medical devices for temporary or permanent implantation and methods of preparing such devices. The methods of the present invention reduce the generation of undesirable radioisotopes by ion implanting a stable isotope having a very high neutron activation cross-section, e.g., at least about 180 barns, or at least about 3000 barns, and then activating the stable isotope by thermal neutron activation to form a radioactive isotope. In a currently preferred embodiment, an implantable therapeutic medical device is prepared by ion-implanting the stable isotope ^{168}Yb , which has a thermal neutron cross-section of 3470 barns, into the body of the device and activating the ^{168}Yb atoms in a nuclear reactor for a time sufficient to produce ^{169}Yb , a soft x-ray emitter with a half-life of approximately 32 days. In an alternate embodiment, a temporarily implanted device is prepared by ion-implanting ^{124}Xe , which has a thermal neutron activation cross-section

of 193 barns, into the outside surface of a wire. Thermal neutron activation of ^{124}Xe generates ^{125}I , a soft X-ray emitter with a half-life of 60 days.

A medical device according to a preferred embodiment of the invention comprises a substrate or body comprising ^{168}Yb , ^{169}Yb , ^{124}Xe , or ^{125}I associated with the body, such as disposed on, incorporated within, or carried with the body. Preferably, the device comprises between about 1×10^{15} and about 5×10^{17} ^{168}Yb atoms. In certain embodiments, the device comprises a concentration of ^{168}Yb at least about 1×10^{16} atoms/cm². In a currently preferred embodiment, the medical device comprises a stent. In an alternate embodiment, wherein the body comprises a source wire, between about 1×10^{17} and about 5×10^{18} atoms of ^{124}Xe per centimeter of length are associated with the wire.

The stable isotope can be any isotope having a sufficiently large neutron activation cross-section so that upon thermal neutron activation, it forms a radioactive isotope having a desirable emission profile in a sufficiently short time that concurrent activation of undesirable isotopes from metals in the body is minimized or avoided. Exemplary isotopes having this property are ^{124}Xe and ^{168}Yb , which are currently preferred.

The body refers to that portion of the device which comprises the underlying structure of said device. The body may be formed from any material suitable for use in medical devices, particularly in implantable medical devices. In a preferred embodiment, the body is formed from one or more materials selected from the group

consisting of metals and metal alloys, organic polymers, and ceramic oxides. Suitable metals and metal alloys comprise, for example, stainless steel, rhodium titanium, chromium, nickel, nitinol, rhenium, and rhenium alloys. Preferred materials comprise stainless steel, rhodium, nitinol, titanium, palladium, and alloys thereof.

5 The devices of the present invention may further comprise a high-density coating. In a preferred embodiment, the high-density coating comprises at least one material selected from the group consisting of titanium, palladium, ytterbium, vanadium, manganese, copper, praseodymium, and rhodium. Preferred materials include titanium, rhodium, and palladium. The high-density coating preferably has a
10 thickness greater than the range of 70 keV beta particles. The high-density coating is preferably between approximately 0.01 micrometers thick and approximately 10 micrometers thick.

 In another embodiment of the invention, an adhesion coating may be disposed between the body and the high density coating. Said adhesion coating is useful for
15 improving the adhesion of the high-density coating to the body. The adhesion coating preferably comprises at least one material selected from the group consisting of aluminum, silicon, titanium, vanadium, palladium, ytterbium, manganese, copper, nickel and rhodium.

 The invention also comprises methods for making medical devices. In one
20 aspect, the method comprises contacting the body with a stable (i.e., non-radioactive) isotope having a high neutron-activation cross-section such as ¹⁶⁸Yb or ¹²⁴Xe under

conditions sufficient to cause the element to become disposed on, associated with, or carried with the body. The body and the isotope are then exposed to a source of thermal neutrons under conditions sufficient to induce activation of the stable isotope, thereby forming a radioactive isotope having a desirable emission profile. In a currently preferred embodiment, wherein ^{168}Yb is used as the stable isotope, thermal neutron activation induces formation of ^{169}Yb , a radioactive isotope having a half-life of about 32 days. In an alternate embodiment, wherein ^{124}Xe is used as the stable isotope, thermal neutron activation induces formation of ^{125}I , a radioisotope having a half-life of about 60 days. The first step of the method may be performed by any suitable method for applying elements to a body or substrate, including, for example, ion-implanting the elements into the body, coating the elements onto the surface of the body, sputtering the elements onto the surface of the body, applying the elements to the body by physical vapor deposition, electroplating the elements onto the surface of the body, or some combination thereof. In a preferred embodiment, the isotope is applied using ion implantation, more preferably during application of a coating of a second metal for increased convenience and reproducibility. The second metal may be any metal suitable for a high-density coating, preferably titanium, palladium, or rhodium.

The second step, wherein the implanted isotopes are activated, preferably is carried out under conditions which induce activation of ^{168}Yb to form ^{169}Yb or which induce activation of ^{124}Xe to form ^{125}I , while minimizing generation of undesirable radioisotopes by activation of metals within the body. In a currently preferred embodiment, a device ion-implanted with ^{168}Yb is exposed to a source of thermal

neutrons for about two hours or less, thereby producing a sufficient therapeutic amount of ^{169}Yb while substantially avoiding formation of undesirable radioisotopes from the elements in the body. In another currently preferred embodiment, a device ion-implanted with ^{124}Xe is exposed to a source of thermal neutrons, thereby producing
5 a sufficient therapeutic amount of ^{125}I while substantially avoiding formation of undesirable radioisotopes from the elements in the body.

A second aspect of the present method further comprises contacting the body with a radioactive isotope, thereby avoiding the thermal neutron activation step. In a preferred embodiment, the body is contacted with ^{169}Yb or ^{125}I under conditions
10 sufficient to cause the ^{169}Yb or ^{125}I to become disposed on, associated with, or carried with the body.

The foregoing methods of the present invention may further comprise the step of applying a high-density coating. The high-density coating may be applied to at least a portion of the body by any coating method, for example by sputtering, physical vapor
15 deposition, electroplating, or some combination thereof. The high-density coating may be applied at any point in the process after the first step. In a preferred embodiment, an adhesion coating is applied prior to applying the high-density coating.

Brief Description Of Drawings

20 FIG. 1 illustrates a side-view and a cross-section of a single wire of a tubular mesh stent, an embodiment of the present invention.

FIG. 2 illustrates a method for ion-implanting ^{168}Yb into a stent.

FIG. 3 illustrates a wire, an embodiment of the present invention.

Detailed Description of the Preferred Embodiments

The present invention overcomes the problems associated with neutron
5 activation of non-radioactive precursor elements disposed on substrates which
themselves are susceptible to neutron activation by employing a stable isotope having a
large neutron activation cross-section, e.g., greater than about 180 barns, or greater
than about 3000 barns, as the non-radioactive precursor. Currently preferred isotopes
are ^{124}Xe and ^{168}Yb , although other isotopes having similar properties can be used. For
10 example, activating ^{168}Yb atoms, which have a neutron activation cross-section of 3470
barns, in a nuclear reactor produces ^{169}Yb , a soft x-ray emitter with a half-life of 32
days. The ^{168}Yb or ^{124}Xe preferably is ion-implanted into the body of the device.
Ordinarily, the technique of ion implanting a device with stable isotopes such as ^{31}P ,
 ^{185}Re , ^{89}Y , or ^{102}Pd in order to produce ^{32}P , ^{186}Re , ^{90}Y , or ^{103}Pd , respectively, by
15 subjecting the device to neutron activation cannot be used with activatable substrates,
because the neutron bombardment will activate elements, such as chromium, iron, and
nickel, in the body to produce long-lived, high-energy gamma ray-emitting isotopes
such as ^{51}Cr and ^{59}Fe , which are unacceptable in a medical device which is intended to
be implanted in a human patient.

20 The present discovery that, for example, a stent containing about 1.5×10^{16}
atoms of an isotope with a high neutron activation cross-section such as ^{168}Yb beneath

the surface of the stent can be activated in a nuclear reactor in less than about two hours renders the process feasible even using a stainless steel body. The use of isotopes having extremely large neutron activation cross-sections allows the duration of the activation to be sufficiently short, e.g., less than about two hours, and preferably less than one hour, that iron, chromium, nickel, and other elements in the device body produce negligible contaminating radiation. Similarly, activation of elements such as iron, chromium, and nickel, which may be present in any adhesion coatings, high density coatings, or other layers of the device is minimized during the shortened duration of neutron activation.

The present method of ion-implanting stable (i.e., non-radioactive) high neutron activation cross-section isotopes followed by thermal neutron activation of the stable isotope to generate a radioisotope having desirable therapeutic profiles has several advantages. For example, in a currently preferred embodiment wherein ^{168}Yb is used, the extremely high thermal neutron activation cross-section of ^{168}Yb , about 3470 barns, allows a substantial reduction in the time required for neutron activation of the precursor element. Furthermore, this property allows the practical utilization of only about 1.5×10^{16} atoms in the near-surface region of the stainless steel body. The nature of ion implantation mass-separates the 0.13% natural abundance of ^{168}Yb from the remaining isotopes of ytterbium, thereby enriching the activatable isotope. Additionally, the sub-surface implantation is deep enough to provide a sealed source, but not deep enough to allow the device body to absorb the soft x-rays, thereby creating a device which emits a substantial amount of x-rays. Ion implantation of ^{124}Xe offers similar advantages.

The term "associated with" as used herein to describe the relationship between the body and the radioisotopes or precursors includes relationships such as infusion, coating, mixture, incorporation, interleaving, envelopment, embedding, diffusion, enclosure, adhesion, imprinting, deposition, electroplating, implantation, and melding
5 of one or more elements with one or more other elements, or any other relationship that implies permanence or semi-permanence of that relationship.


The body useful in the medical device of the present invention comprises a structure, device, or article having characteristics, such as stability, resiliency, structure, and shape, suitable for its intended use. The body may comprise a stent,
10 seeds, wire, or other articles suitable for implantation in a patient to deliver a localized dose of radiation. In one embodiment, the body is made from metals and metal alloys, for example, titanium alloy, titanium-vanadium-aluminum alloy, rhodium, vanadium, palladium, rhenium, aluminum, nickel, nitinol (NiTi), stainless steel, and alloys of stainless steel such as type 404. Preferred metal alloys include stainless steel, rhodium,
15 palladium, titanium, Ti-6-4, which is 90% titanium, 6% vanadium, and 4% aluminum, and nitinol, which is 50% nickel and 50% titanium. In another embodiment, the body may comprise one or more materials selected from the group comprising organic polymers and ceramic oxides, such as quartz (silicon dioxide), alumina (aluminum oxide), titania (titanium dioxide), and zirconia (zirconium oxide). A body may further
20 comprise one or more elements, e.g., ytterbium-168, xenon-124, barium-130, phosphorus-31, palladium-102, yttrium-89, rhenium-185, rhenium-187, and tungsten-186, which can be neutron-activated to radioactive isotopes.

In a currently preferred embodiment, the body comprises a stent, said stent being a medical device that can be placed within the lumen of a tubular structure to provide support during or after anastomosis or catheterization, or to assure patency of an intact but contracted lumen. FIG. 1 shows an example of a stent used in coronary arteries. In this embodiment, the shape of the body may be a tubular mesh shape, a helical coil shape, or any of a variety of other shapes suitable for a stent. In another preferred embodiment, the body comprises a wire, the wire being a medical device that can be inserted into a lumen of a tubular structure to deliver a dose of radiation. FIG. 3 shows an example of such a wire.

The body comprises radioactive isotopes to provide therapeutic or a prophylactic radiation treatment to a subject. For example, a radioactive stent may be implanted in a blood vessel after angioplasty to inhibit restenosis. In one embodiment, the implantable medical device preferably comprises a body that is initially formed from a non-radioactive structural material. One or more stable, non-radioactive precursor isotopes are added into the body or onto the body of the medical device under conditions sufficient to cause the isotope to become associated with the body. The precursor isotopes associated with the body of the medical device are activated by exposing the body to a source of thermal neutrons. In another embodiment, one or more radioactive elements are added to the body or onto the body, thereby eliminating the need for the activation step. In yet another embodiment, coatings that enhance the safety and/or performance of these medical devices may be applied to the devices.


The criteria for selection of a stable precursor element that is to be neutron-activated include: having a half-life between about two and about thirty days, or between about two and about seventy days; having a high neutron activation cross-section; and having the resultant radioisotope primarily emit beta particles or x-rays rather than gamma rays. Beta particles and x-rays provide a short-range dose to tissue, and thus the entire body of the patient does not receive a radiation dose unnecessarily. Radioisotopes that meet these criteria to a greater or lesser extent comprise phosphorous-32, phosphorous-33, sulfur-32, and rhenium-186. Phosphorous-32 has a low neutron activation cross-section, phosphorous-33 is difficult to produce, sulfur-32 has too long a half-life, and rhenium-186 produces 20% of its radiation as gamma rays. Preferred non-radioactive precursor isotopes include ytterbium-168, xenon-124, barium-130, phosphorus-31, palladium-102, yttrium-89, rhenium-185, rhenium-187, and tungsten-186, most preferably ytterbium-168 and xenon-124.

For both ^{168}Yb and ^{124}Xe , neutron activation leads to an isotope which is primarily a soft x-ray emitter as a result of electron capture decay. In the case of ^{168}Yb , the reaction is:



Thus, the stable precursor and the radioactive product are of the same element, i.e., ytterbium.

In the case of neutron activation of ^{124}Xe , however, the useful radioactive product is a different element, because the process involves a preliminary decay step:



Thus, in the case of ^{124}Xe , after about 10 half-lives of ^{125}Xe , i.e., 171 hours or about one week, almost all of the ^{125}Xe will have decayed to ^{125}I , which has a half-life of about 60 days and emits essentially pure 31 keV x-rays from electron capture decay without gamma or beta emissions.

The non-radioactive precursor isotope may include some percentage of other isotopes. A non-radioactive precursor isotope may be optionally added to the body of the medical device by either incorporating a small quantity of the isotope into the molten alloy precursor from which the body of the medical device is fabricated, thermally diffusing the isotope into the body of the medical device, ion-implanting with isotope mass separation below the surface of the body of the medical device, or coating the surface of the body of the medical device. Other methods for adding a non-radioactive isotope to the body of the medical device, such as electroplating or sputtering, may also be employed, either alone or in combination.

The quantity of desired non-radioactive isotope to be added to the implantable medical device body varies with the size of the body of the medical device. For

example, a typical stent requires about ten to fifty micrograms of rhenium-185 or nearly five milligrams of phosphorous-31, with the difference primarily being related to the activation cross-section and half-life. Adding as much of a desired non-radioactive isotope as possible while avoiding a significant alteration in the desired physical and chemical properties of the medical device body is preferable for minimizing neutron activation time and minimizing the incidental activation of contaminating species in the medical device body. Isotopically enriched additions of non-radioactive precursor isotopes, such as enriched ytterbium, obtained through the use of mass-analyzed ion implantation, may be employed to advantage and are preferred.

When the medical device body is thermal neutron-activated, both the precursor isotope and any activatable impurity isotopes in the body may become radioactive. If the quantity or neutron activation cross-section of a precursor isotope is increased, the required level of the radioactive isotope can be obtained with less neutron activation time. This in turn results in lower radioactivity levels due to impurities in the medical device body. The quantity of non-radioactive precursor isotope is most easily increased by combining several of the methods described for precursor addition. In a preferred embodiment for coatings, another high-density coating material such as rhodium, palladium, or titanium would be sputtered either simultaneously or during a portion of the ion implantation, such that the external surface of the high-density coating would consist solely of a biologically inert element.

Ordinarily, heavy atoms cannot be implanted into steel at doses exceeding $1 \times 10^{17}/\text{cm}^2$ because of the excessive sputtering of material from the surface by the ion

beam. At a dose above $1 \times 10^{17}/\text{cm}^2$, the number of heavy atoms incident is equal to the number sputtered away and therefore the heavy atoms cease to accumulate on the body ("Mechanical and Chemical Properties of Tantalum Implanted Steels", Hubler G. K., and Singer I. L., Materials Science and Engineering, 60 (1985) 203-210). Ion
5 implantation of ^{124}Xe , a gas at room temperature, has the additional limitation that the concentration of Xe cannot exceed a certain solubility in the substrate. However, if ion implantation is performed while simultaneously depositing a coating of a second metal or metal alloy (see U.S. Patent No. 5,383,934, hereby incorporated herein by
10 reference), the sputter loss then consists of atoms from the growing coating rather than those being ion-implanted, yielding improved retention of implanted ytterbium-168 atoms. Using this technique, it is possible to ion implant up to $1 \times 10^{18}/\text{cm}^2$ Yb atoms into a stainless steel stent. In the case of ^{124}Xe , the simultaneous coating supplies additional material so that the concentration of Xe typically does not exceed 20
15 atom%. The second metal or metal alloy is preferably chosen from among elements which do not become substantially radioactive when exposed to a source of thermal neutrons. Metals which may be useful in this capacity include, for example, palladium, titanium, and rhodium.

An example of the above technique is depicted in Figure 2. In this exemplary
20 practice, the stent 1 is mounted in a vacuum chamber and rotated about horizontal axis 2 at a speed of approximately 10 rpm. The horizontal ^{168}Yb ion beam 3 is incident upon the stent with an energy of 90 keV and a current density of approximately $1 \mu\text{A}/\text{cm}^2$. At this rate, the required dose of $4.3 \times 10^{16}/\text{cm}^2$ can be accumulated in 1.9 hours while depositing a coating approximately 2000 Å thick. Concurrent with the ion

bombardment, an evaporation hearth 4 evaporates titanium metal 5 at a rate of 0.3 Å/sec/cm² for the entire 1.9 hour procedure. The resulting stent will contain approximately 1.5×10^{16} atoms of ¹⁶⁸Yb embedded into its outer surface. Use of this technique for the ion implantation of ¹²⁴Xe, wherefor a layer typically between 5 and 20
5 microns thick is deposited, is similarly advantageous. Procedures achieving an equivalent result will be apparent to those of skill in the art.

The amount of exposure required for neutron activation of the medical device depends on the flux rate of the nuclear reactor used, the thickness and composition of the coating applied to the body, the neutron activation cross-section of the precursor
10 element, and the amount of beta radiation desired. The exposure time could range from a few minutes in a very high flux reactor to several hours in a low flux reactor.

When the radioactive isotopes are produced by neutron activation of the entire medical device in a nuclear reactor, the bulk material of the medical device may also be activated. If the medical device body contains significant quantities of nickel,
15 undesirable long-lived emissions of nickel-63 typically are produced during prolonged periods of activation. This isotope decays solely by beta decay with no gamma radiation. The beta end-point energy is 66.9 keV. Without blocking the nickel-63 beta particles, the particles would continuously bombard the patient for the lifetime of the patient, because the half-life of nickel-63 is 100 years. Reducing the activation time is
20 thus advantageous.

Nickel also is sometimes considered to be a source of undesirable metal ions in the human body. In nitinol, the nickel is stabilized in the form of a compound. In the present invention, it is desirable to provide a coating of a protective, biologically inert material to reduce or eliminate the risk of nickel dissolution into the bloodstream or other bodily fluids.

If the medical device body contains a significant quantity of nickel, a coating of a high-density material may be applied over at least a portion of the body. The coating of high-density material may serve several useful purposes, including containment of undesirable beta particles from long-lived radioactive species, creation of a biologically inert surface, and enhancement of x-ray radiopacity to improve the visibility of the implantable medical device. In a preferred embodiment, a coating of high-density material is used to block the passage of beta particles from nickel-63 into the surrounding tissue by covering essentially all of the exposed surface of the medical device with the high-density material. In one embodiment, the coating of high-density material may be applied prior to neutron activation. In another embodiment, the coating is applied after neutron activation.

If the high-density coating is applied after neutron activation of the medical device body, it may be fabricated in combination or individually of gold, platinum, iridium, or rhenium in addition to those elements that may be used for coating before neutron activation, e.g., rhodium, titanium, vanadium, manganese, copper, and praseodymium. The required properties are high-density, high atomic number, chemical inertness, and adhesion strength. The high-density coating may have a

thickness preferably between about 0.01 micrometer and about 30 micrometers, more preferably between 0.01 micrometers and 10 micrometers. If the thickness of the high-density coating is between five micrometers and twenty micrometers, it may also be utilized as a radiopaque material to improve x-ray visibility. In a preferred embodiment, the thickness is greater than the range of 70 keV beta particles, for example about 8.4 micrometers for gold and about 10 micrometers for rhodium. The advantage of applying the high-density coating after neutron activation is the freedom to select the highest density materials. The disadvantage is that personnel must handle a radioactive device during the coating procedure.

10 An alternate embodiment would involve application of a high-density coating prior to neutron activation of the medical device body. This alternate embodiment requires that the elements in the high-density coating must not activate significantly to any undesired radioisotopes during the required activation period. Minimizing the activation period thus becomes advantageous. If the high-density coating is also to be used for radiopacity, the coating requires sufficient density and thickness to exhibit good x-ray visibility. Examples of such elements, which may be employed in combination or individually, are rhodium, titanium, vanadium, manganese, copper, and praseodymium. Rhodium or an alloy of rhodium-copper are preferred within this group. Rhodium has a density of 12.4, copper has a density of 9.0, and both are mutually miscible in all proportions. The copper is included to increase the ductility and reduce the stiffness of the rhodium. Neutron activation of stable rhodium-103 produces rhodium-104, which has a 4.3 minute half-life. Neutron activation of stable copper-63 produces copper-64, which has a 12.7 hour half-life. Neutron activation of

stable copper-65 produces copper-66, which has a 5.1 minute half-life. While rhodium has a lower density than gold or platinum, rhodium is more efficient at attenuating x-rays in the energy range between approximately 30 to 80 keV, which is in the central portion of a 120 keV tungsten bremsstrahlung x-ray spectrum commonly employed for medical imaging. As a consequence, rhodium and gold coatings of equal thickness are typically within five to ten percent of one another in terms of x-ray radiopacity.

In another embodiment, a gold coating is applied to enhance the x-ray image. In a preferred embodiment, a gold coating approximately ten to fifteen micrometers in thickness on the medical device body significantly enhances the x-ray image. Gold is a very soft metal, and a thickness of ten to fifteen microns should not contribute additional structural stiffness to the body of the medical device. If the medical device body is a stent, it should have considerable stiffness in order to hold open the elastic artery. In order to effect good adhesion of the gold coating to the medical device body, it is desirable to first coat the structure with a thin coating of titanium about 3000 Angstroms thick before depositing the thicker gold coating. Titanium has been found to promote adhesion to nitinol stents. Both the adhesion-promoting layer and the gold coating can be deposited using an unbalanced magnetron sputtering process in vacuum.

Optionally, one or more adhesion layers may be disposed on the body to promote adhesion of the non-radioactive precursor isotope, the high-density coating material, and/or the radioactive isotope. The adhesion layer may be formed a material that includes silicon, aluminum, titanium, vanadium, nickel, praseodymium, or rhodium

when used between the body and the non-radioactive precursor isotope or the radioactive isotope. The adhesion layer preferably comprises silicon, titanium, vanadium, chromium, iron, cobalt, or nickel when used between the body of the medical device and the high-density coating material.

5 The selection of high-density coating materials and adhesion layer materials is dependent on whether these materials will be subjected to neutron activation and the duration of said neutron activation period. Preferably, the therapeutic isotopes will have half-lives between one day and forty days. If materials in either the high-density coating or the adhesion layer are susceptible to being neutron-activated to radioactive
10 isotopes, it is preferable that the half-lives of any such radioactive isotopes be shorter than about one day, so that these isotopes can be expected to decay to insignificant activity levels before the device is implanted. The elements aluminum, silicon, titanium, vanadium, manganese, copper, praseodymium, and rhodium meet the criterion of short half-life.

15 The following example further illustrates the invention, and is not intended to be limiting in any way.

Example 1

A conventional stainless steel stent (available from Guidant Corp. Multilink,

or Cordis) can be processed according to the following example:

5	stent mass:	0.015 gram
	material:	316L stainless steel
	surface area:	0.35 cm ²
	¹⁶⁸ Yb ion implant dose:	4.3 x 10 ¹⁶ /cm ²
	ion implantation energy:	90 keV
	simultaneous coating of Ti:	2000 Å
	¹⁶⁸ Yb atoms in surface:	1.5 x 10 ¹⁶ atoms
10	thermal neutron dose rate:	8 x 10 ¹³ neutrons/cm ² /sec
	thermal neutron dose duration:	1 hour
	post-activation decay time:	7 days
	¹⁶⁹ Yb initial activity:	84 µCi

The resulting stent produces a total dose to the adjacent tissue of approximately 25 Grays 2 mm from the outer surface of the stent, which is within the accepted therapeutic range.

Exposure to neutron activation preferably does not activate the stainless steel stent body significantly. Indeed, when the stent is activated for one hour at a neutron dose rate of 8 x 10¹³ neutrons/cm²/sec, the total gamma ray activity from the alloy constituents is:

From 74% iron in stainless steel:	0.5 μCi of ^{59}Fe
From 18% chromium in stainless steel:	3.5 μCi of ^{51}Cr
From 8% nickel in stainless steel:	0.009 μCi of ^{63}Ni

Other trace contaminants such as Mn and Si produce even less radioactivity.

5 Example 2

For temporary intra-vascular brachytherapy, a 2.5 cm-long wire can be prepared which emits only soft x-rays (32 keV) from ^{125}I using the following parameters:

	wire diameter:	0.010 inch
10	material:	rhodium
	^{124}Xe atoms in surface:	1×10^{18} atoms
	ion implantation energy:	90 keV
	simultaneous coating of Ti:	15 microns
	thermal neutron dose rate:	2×10^{15} neutrons/cm ² /sec
15	thermal neutron dose duration:	30 days
	post-activation decay time:	7 days
	^{125}I initial activity:	7 Ci
	Activity per unit length:	2.8 Ci/cm

The resulting wire source, when placed into an angioplasty site using an appropriate catheter, can provide a dose of 25 Grays 2 mm from the wire in less than 30 minutes, which is within the accepted therapeutic range.

Equivalents

- 5 While the invention has been disclosed in connection with the preferred embodiments shown and described in detail, various equivalents, modifications, and improvements will be apparent to one of ordinary skill in the art from the above description. Such equivalents, modifications, and improvements are intended to be encompassed by the following claims.

What is claimed is:

1. A medical device comprising a body and at least one isotope associated with the body, wherein the isotope has a neutron activation cross-section of at least about 180 barns.
- 5 2. A medical device comprising a body and at least one isotope associated with the body, wherein the isotope has a neutron activation cross-section of at least about 3000 barns.
3. A medical device comprising a body and at least one isotope of ytterbium selected from the group consisting of ^{168}Yb and ^{169}Yb associated with said
10 body.
4. A medical device comprising a body and at least one isotope selected from the group consisting of ^{125}I and ^{124}Xe associated with said body.
5. The device of claim 3, wherein the isotope is ion-implanted.
6. The device of claim 4, wherein the isotope is ion-implanted

7. The device of claim 1, wherein said body comprises a material selected from the group consisting of organic polymers, ceramic oxides, metals, and metal alloys.
8. The device of claim 4, wherein said body comprises stainless steel, titanium, or nitinol.
9. The device of claim 4, wherein said body comprises rhodium, palladium, or a palladium alloy.
10. The device of claim 3, wherein the amount of ytterbium associated with the body is between about 1×10^{15} and about 5×10^{17} atoms.
11. The device of claim 3, wherein the concentration of ytterbium associated with the body is at least about 1×10^{16} atoms/cm².
12. The device of claim 4, wherein the amount of ^{124}Xe associated with the body is between about 1×10^{17} and about 5×10^{18} atoms per centimeter of length.
13. The device of claim 1, further comprising a high-density coating applied to at least a portion of the body.
14. The device of claim 13, further comprising an adhesion coating disposed between said body and said high density coating.

15. A method of making a medical device, comprising:
- (a) contacting a body with at least one isotope, wherein the isotope has a neutron activation cross-section of at least about 180 barns under conditions sufficient to cause said isotope to become associated with the body; and
 - 5 (b) exposing the body and the associated isotope to a source of thermal neutrons under conditions sufficient to generate a radioisotope.
16. A method of making a medical device, comprising:
- (a) contacting a body with at least one isotope, wherein the isotope has a neutron activation cross-section of at least about 3000 barns under conditions
 - 10 sufficient to cause said isotope to become associated with the body; and
 - (b) exposing the body and the associated isotope to a source of thermal neutrons under conditions sufficient to generate a radioisotope.
17. A method of making a medical device, comprising:
- (a) contacting a body with at least isotope selected from the group
 - 15 consisting of ^{124}Xe or ^{168}Yb under conditions sufficient to cause said isotope to become associated with the body; and
 - (b) exposing the body and the associated isotope to a source of thermal neutrons under conditions sufficient to generate a radioisotope.
18. The method of claim 17, wherein act (a) comprises ion-implanting ^{168}Yb into
- 20 the body.

19. The method of claim 17, wherein act (a) is performed by one technique selected from the group of adding ^{168}Yb to the molten metal alloy of the medical device body, coating ^{168}Yb onto the surface of the body, sputtering of ^{168}Yb onto the surface of the body, applying ^{168}Yb to the body by physical vapor deposition, and electroplating ^{168}Yb onto the surface of the body.
20. The method of claim 17, wherein act (a) is performed by ion-implanting at least one isotope selected from the group consisting of ^{168}Yb and ^{124}Xe onto the surface of the body while simultaneously depositing a coating of a second metal or metal alloy.
21. The method of claim 20, wherein the second metal or metal alloy consists essentially of elements that do not become substantially radioactive when exposed to a source of thermal neutrons.
22. The method of claim 20, wherein the second metal or metal alloy comprises one or more metals selected from the group consisting of palladium, titanium, and rhodium.
23. The method of claim 13, further comprising applying a high-density coating to at least a portion of the body.
24. The method of claim 22, further comprising the step of applying an adhesion coating between the body and the high-density coating.

1/2




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/2




FIG. 2



FIG. 3

SUBSTITUTE SHEET (RULE 26)

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 51/12, 41/00	A3	(11) International Publication Number: WO 99/39765 (43) International Publication Date: 12 August 1999 (12.08.99)
---	-----------	--


(21) International Application Number: **PCT/US99/02788**(22) International Filing Date: **9 February 1999 (09.02.99)**(30) Priority Data:
60/074,181 **10 February 1998 (10.02.98)** **US**(71) Applicant: **IMPLANT SCIENCES CORPORATION [US/US];**
107 Audubon Road #5, Wakefield, MA 01880-1246 (US).(72) Inventor: **ARMINI, Anthony, J.; 5 Skytop Drive, Manches-**
ter-by-the-Sea, MA 01944 (US).(74) Agent: **CAMPBELL, Paula, A.; Foley, Hoag & Eliot, LLP,**
One Post Office Square, Boston, MA 02109 (US).(81) Designated States: **AL, AM, AT, AU, AZ, BA, BB, BG, BR,**
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW,
ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN,
TD, TG).**Published***With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(88) Date of publication of the international search report:

30 September 1999 (30.09.99)(54) Title: **SOFT X-RAY EMITTING MEDICAL DEVICES**

(57) Abstract

An implantable medical device according to the present invention comprises a body, such as a stent or a wire, and an isotope having a high neutron activation cross section, such as ¹⁶⁸Yb or ¹²⁴Xe, ion-implanted onto the surface of the body. The use of isotopes having high neutron activation cross sections allows a wider choice of substrates to be employed, including stainless steel, nickel, titanium, and alloys including these metals, because the time required for neutron activation of the device is reduced. A coating of high-density material may be incorporated to serve several useful purposes, including containment of undesirable beta particles from long-lived radioactive species, creation of a biologically inert surface, and enhancement of x-ray radiopacity to improve the visibility of an implanted medical device. The implantable medical devices of the present invention also comprise radioactive medical devices which include radioisotopes such as ¹⁶⁹Yb and ¹²⁵I.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

II. national Application No

PCT/US 99/02788

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K51/12 A61K41/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 99 02195 A (IMPLANT SCIENCES CORP ; ARMINI ANTHONY J (US)) 21 January 1999 (1999-01-21) cited in the application ---	1-9, 13-16
X	US 5 674 177 A (HEHRLEIN CHRISTOPH ET AL) 7 October 1997 (1997-10-07) column 2, line 63 - line 68; claims 1-3; tables 1,2 ---	1,2,7,8
X	EP 0 593 136 A (FISCHELL ROBERT ; FISCHELL TIM A (US)) 20 April 1994 (1994-04-20) column 2, line 25 - line 54; claims --- -/--	1-3,7,8, 10,11, 15,16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 August 1999

Date of mailing of the international search report

16/08/1999

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/02788

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SOLOWAY A H ET AL: "THE CHEMISTRY OF NEUTRON CAPTURE THERAPY" CHEMICAL REVIEWS, vol. 98, no. 4, 1 June 1998 (1998-06-01), pages 1515-1562, XP000754987 ISSN: 0009-2665 table 1	1
X	US 3 351 049 A (D.C. LAWRENCE) 7 November 1967 (1967-11-07) column 3, line 14 - line 36 column 8, line 37 - line 44	1
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US DN=121:128891, KAGEHIRA, KATSUSHI ET AL: "Dose evaluation in gadolinium neutron capture therapy" retrieved from STN Database accession no. 121:128891 XP002110395 abstract & KYOTO DAIGAKU GENSHIRO JIKKENSHO GAKUJUTSU KOENKAI HOBUNSHU (1994), 28, 187-96 ,	1
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US DN=120:128541, NATH, RAVINDER ET AL: "Dosimetric characteristics of a double wall iodine-125 source for interstitial brachytherapy" retrieved from STN Database accession no. 120:128541 XP002110396 abstract column 3, line 1 - line 16 & MED. PHYS. (1993), 20(5), 1475-83 ,	1,2,4, 6-8, 14-16
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN=1995:365412, MACPHERSON, M. S. (1) ET AL: "Dose distributions and dose rate constants for new ytterbium-169 brachytherapy seeds." retrieved from STN XP002110397 abstract & MEDICAL PHYSICS (NEW YORK), (1995) VOL. 22, NO. 1, PP. 89-96. ,	1-3,7,8, 10,11, 15,16

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/02788

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MUMPER R J ET AL: "NEUTRON-ACTIVATED HOLMIUM-166-POLY (L-LACTIC ACID) MICROSPHERES: A POTENTIAL AGENT FOR THE INTERNAL RADIATION THERAPY OF HEPATIC TUMORS"</p> <p>JOURNAL OF NUCLEAR MEDICINE, vol. 32, no. 11, 1 November 1991 (1991-11-01), pages 2139-2143, XP000240389</p> <p>ISSN: 0161-5505</p> <p>figures</p>	1,2,7,15
X	<p>CHENG, K. Y. (1) ET AL:</p> <p>"Neutron-activatable glass seeds for brachytherapy."</p> <p>JOURNAL OF NUCLEAR MEDICINE, (1994) VOL. 35, NO. 5 SUPPL., PP. 242P-243P. MEETING INFO.: 41ST ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE ORLANDO, FLORIDA, USA JUNE 5-8, 1994 , XP002111090</p> <p>abstract</p>	1,2,7,15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/02788

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-24 relate to an extremely large number of possible devices. In fact, the claims contain so many options, that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely..... e.g those compounds or products recited in the examples and closely related homologous compounds.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/02788

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9902195	A	21-01-1999	AU 8656798 A	08-02-1999
US 5674177	A	07-10-1997	DE 4315002 C	18-08-1994
			AT 151620 T	15-05-1997
			WO 9426205 A	24-11-1994
			EP 0696906 A	21-02-1996
			JP 2735689 B	02-04-1998
			JP 8508436 T	10-09-1996
EP 0593136	A	20-04-1994	US 5059166 A	22-10-1991
			AT 108635 T	15-08-1994
			AT 149365 T	15-03-1997
			AU 624310 B	04-06-1992
			AU 6795390 A	13-06-1991
			CA 2031891 A	12-06-1991
			DE 69010864 D	25-08-1994
			DE 69010864 T	10-11-1994
			DE 69030118 D	10-04-1997
			DE 69030118 T	12-06-1997
			DK 433011 T	31-10-1994
			EP 0433011 A	19-06-1991
			ES 2058822 T	01-11-1994
			ES 2097972 T	16-04-1997
			JP 2803366 B	24-09-1998
			JP 4126139 A	27-04-1992
			US 5176617 A	05-01-1993
US 3351049	A	07-11-1967	NONE	